240 related articles for article (PubMed ID: 19552944)
1. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.
Sfakianos GP; Numnum TM; Halverson CB; Panjeti D; Kendrick JE; Straughn JM
Gynecol Oncol; 2009 Sep; 114(3):424-6. PubMed ID: 19552944
[TBL] [Abstract][Full Text] [Related]
2. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
Richardson DL; Backes FJ; Hurt JD; Seamon LG; Copeland LJ; Fowler JM; Cohn DE; O'Malley DM
Gynecol Oncol; 2010 Jul; 118(1):47-51. PubMed ID: 20382413
[TBL] [Abstract][Full Text] [Related]
3. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
Simpkins F; Belinson JL; Rose PG
Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
[TBL] [Abstract][Full Text] [Related]
4. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma.
Diaz JP; Tew WP; Zivanovic O; Konner J; Sabbatini PJ; dos Santos LA; Abu-Rustum NR; Chi DS; Aghajanian C; Barakat RR
Gynecol Oncol; 2010 Mar; 116(3):335-9. PubMed ID: 20004956
[TBL] [Abstract][Full Text] [Related]
5. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers.
Kudoh K; Takano M; Kouta H; Kikuchi R; Kita T; Miyamoto M; Watanabe A; Kato M; Goto T; Kikuchi Y
Gynecol Oncol; 2011 Aug; 122(2):233-7. PubMed ID: 21601912
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
Chura JC; Van Iseghem K; Downs LS; Carson LF; Judson PL
Gynecol Oncol; 2007 Nov; 107(2):326-30. PubMed ID: 17706754
[TBL] [Abstract][Full Text] [Related]
7. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer.
Matulonis UA; Pereira L; Liu J; Lee H; Lee J; Whalen C; Campos S; Atkinson T; Hill M; Berlin S
Gynecol Oncol; 2012 Jul; 126(1):41-6. PubMed ID: 22487536
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
Asmane I; Kurtz JE; Bajard A; Guastalla JP; Meeus P; Tredan O; Labidi Galy I; Moullet I; Ardisson P; Vincent L; Coeffic D; Dufresne A; Bergerat JP; Ray-Coquard I
Bull Cancer; 2011 Oct; 98(9):80-9. PubMed ID: 21926034
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM
J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643
[TBL] [Abstract][Full Text] [Related]
10. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer.
Hurt JD; Richardson DL; Seamon LG; Fowler JF; Copeland LJ; Cohn DE; Eisenhauer E; Salani R; O'Malley DM
Gynecol Oncol; 2009 Dec; 115(3):396-400. PubMed ID: 19804901
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
[TBL] [Abstract][Full Text] [Related]
14. [Bowel perforation associated with bevacizumab therapy in recurrent ovarian cancers without bowel obstruction or bowel involvement].
Takano M; Kikuchi Y; Kato M; Yoshikawa T; Kita T
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1981-4. PubMed ID: 19011357
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: a retrospective study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group.
Pietzner K; Richter R; Chekerov R; Erol E; Oskay-Özcelik G; Lichtenegger W; Sehouli J
Anticancer Res; 2011 Aug; 31(8):2679-82. PubMed ID: 21778323
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
Cannistra SA; Matulonis UA; Penson RT; Hambleton J; Dupont J; Mackey H; Douglas J; Burger RA; Armstrong D; Wenham R; McGuire W
J Clin Oncol; 2007 Nov; 25(33):5180-6. PubMed ID: 18024865
[TBL] [Abstract][Full Text] [Related]
17. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
August DA; Serrano D; Poplin E
J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
[TBL] [Abstract][Full Text] [Related]
18. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
